All > Massachusetts Investigators

Mary Buss, MD, MPH

Beth Israel Deaconess Medical Center

Boston, Massachusetts - 02215

CLINICAL TRIALS 1
CONDITIONS4
INTERVENTIONS2
SINCE2009

Cediranib and Olaparib in Combination for Recurrent Ovarian or Triple-Negative Breast Cancer

November 2009 - October 2014

Breast Neoplasms

Ovarian Neoplasms

Peritoneal Neoplasms

Fallopian Tube Neoplasms

Cediranib

Olaparib

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Mary Buss, MD, MPH

Beth Israel Deaconess Medical Center

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP